The CD40/CD40 ligand (CD40L) costimulatory system, which amplifies immune responses and can induce inflammation, is believed to have a role in skin manifestations of other autoimmune diseases ...

糖尿病，尤其是1型糖尿病（T1D），一直是一个困扰全球数百万患者的慢性疾病。许多患者每天需要注射胰岛素来控制血糖水平，这不仅给生活带来了不便，还伴随着一系列潜在的健康风险。那么，有没有可能让这些患者彻底摆脱胰岛素呢？最近的一项研究或许为我们带来了答案。 想象一下，如果有一种方法能够让糖尿病患者不再依赖胰岛素，那将是一个多么令人振奋的消息！近日，Eledon Pharmaceuticals公司公布了 ...

今日，Eledon ...

One such molecule is the CD40L, which engages CD40 on dendritic and B cells of the immune system, enabling T cells to become activated as a result. Rodent studies using coreceptor blockade with ...

研究发现，cd40l从tfh转移至b淋巴细胞需要持续的cd40信号，并使抗原提呈b淋巴细胞在gc中存活和增殖。 CD40L从T淋巴细胞转移至B淋巴细胞的机制可能 ...

Frexalimab is described by Sanofi as a ‘second-generation’ anti-CD40L antibody that can block the costimulatory CD40/CD40L cellular pathway necessary for adaptive and immune cell activation ...

CD40–CD40L signaling may regulate both the initiation and effector phases of B- and T-cell responses, as well as transmigration of activated cells to target tissues. Direct therapy against this ...

Leerink Partners analyst Thomas Smith has reiterated their bullish stance on ELDN stock, giving a Buy rating yesterday. Thomas Smith’s ...

The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad ...

加利福尼亚州尔湾 - Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)已为一项重大的承销发行定价,包括超过1800万股普通股和用于购买额外股份的预付权证,旨在筹集约8500万美元。普通股的定价为每股3.65美元,而预付权证的报价为每份3.649美元,可以0.001美元的价格行权购买每股。 这项财务举措计划于2024年10月30日完成交割,前提是满足标准的交割条件 ...